Peripheral nerve dysfunction in chronic kidney disease by Lakshmi Priya, M
DISSERTATION ON PERIPHERAL NERVE DYSFUNCTION 
STUDY IN CHRONIC KIDNEY DISEASE  
 
 
M.D.  DEGREE EXAMINATION BRANCH – 1 
GENERAL MEDICINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tirunelveli Medical College  
Tamilnadu Dr. M.G.R Medical University  
Chennai, Tamilnadu  
March 2007 
 
 
 
TIRUNEVLEI MEDICAL COLLEGE  
TIRUNELVELI – 627 011. 
 
 
 
CERTIFICATE  
 
 
 
                  This is to certify that this dissertation entitled  
“PERIPHERAL NERVE DYSFUNCTION IN CHRONIC KIDNEY 
DISEASE” is a bonafide record of work done by DR. M. LAKSHMI PRIYA 
under my guidance and supervision in Tirunelveli Medical College Hospital 
during the period of her post graduate study for M.D. (General Medicine) from 
2004 -2007. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ACKNOWLEDGEMENT 
 
 
 I whole heartedly thank THE DEAN, Tirunelveli Medical College, for 
having permitted me to carry out this study at Tirunelveli Medical College.  
 
 I am greatly indebted to my Professor and Head of the Department of 
Medicine, Dr. V. UMADEVI, M.D., for having guided me patiently throughout 
the period of this work.   
 
 I thank all the professors and Assistant Professors of Medicine for their 
expert guidance and valuable help.  
 
 I thank the technical staff of central laboratory for their co-operation and 
help in the study.  
 
 Last but not the least I thank all my patients for their kind co-operation in 
carrying out this study successfully.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE OF CONTENTS  
 
 
 
 
S.NO TITLE   
1.             Aim of the study  
2.             Introduction   
3.             Review of literature  
4.             Materials and Methods   
5.             Observation   
6.             Discussion   
7.             Conclusion  
8.             Summary  
9.             Bibliography  
10.             Proforma   
11.             Master chart  
   
   
AIMS OF THE STUDY 
This study is aimed:  
 
1) To evaluate the incidence of overt neuropathy and subclinical 
neuropathy in chronic kidney disease patients attending our hospital. 
 
2) To evaluate the clinical manifestations of peripheral nerve 
dysfunction in chronic kidney disease patients attending our hospital.  
 
3) To correlate the incidence of peripheral neuropathy with 
reference to the severity and duration of the chronic kidney disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
   Peripheral nerve dysfunction is a recognised complication of  
chronic kidney disease Most of the time, patients who are having features of 
peripheral nerve dysfunction won’t come out with complaints of it, unless it is 
specifically asked or looked for. Since the year 1962 various authors have 
already discussed about the prevalence, incidence, clinical features and 
pathology of peripheral nerve dysfunction in chronic kidney disease.   
 
 In our hospital, more than 1000 patients for 2 years fulfilling the criteria 
for chronic kidney disease are treated as inpatient or outpatient.  
 
 At present the medical treatment for kidney disease is improving and 
patient’s long term survival is improving.  Peritoneal dialysis,  heamodialysis 
and transplantation have revolutioned the prognosis of chronic Kidney disease 
in recent periods. As patients life span is prolonged due to recent improvement 
in treatment of chronic kidney disease, it is essential to know about the 
complication that can occurr in patient surviving for long period with chronic 
kidney disease of which peripheral nerve dysfunction is one of the recognizable 
and treatable complication of chronic kidney disease.    The Etiology of chronic 
kidney disease is varying in nature, but the clinical symptoms and signs are of 
same. 
 
 The study mainly focuses the incidence, clinical manifestation and 
severity of peripheral nerve dysfunction in patient with chronic kidney disease 
admitted in out hospital.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HISTORICAL REVIEW OF THE LITERATURE 
 
 A decade ago the first experimental programs in haemodialysis for 
chronic kidney disease were in progress.  Hegstrom and coworkers (1962)14, 15  
in Seattle, noted that all their original four patients developed some signs of 
polyneuropathy, one to a disabling degree.  There was grave concern at first that 
the procedure of dialysis itself might be culpable, but intensifying dialysis 
produced some amelioration.  At about the same time, Asbury victor and dams 
(1962, 1963)16, 17  described the clinical and pathologic features of 
polyneuropathy associated with chronic kidney disease in four patients.  The 
important points about these cases were, first, that none of the patients had 
undergone haemodialysis, and second, that the basis for kidney disease was 
diverse, including chronic obstructive uropathy with pyelonephritis, chronic 
glomerulonephritis, and hereditary interstitial nephritis.  Thus, it appeared that 
chronic kidney disease could by itself be responsible for polyneuropathy, and 
haemodialysis was absolved of being the primary offender.  
 
 In an earlier report, Martin and Tyler (1961) also had described severe 
polyneuropathy, in two young men with hereditary interstitial nephritis, 
although they thought the neuropathy was related to the underlying hereditary 
disorder rather than being due to the uremic state.  Both their patients underwent 
dialysis, but only after the neurologic symptoms were well established.  
 
 More recently, in a prospective study of patients with relatively mild 
renal insufficiency who were treated conservatively without dialysis, Hebsen, 
takeoff, and Honet (1967)18 showed that rising serum creatinine levels 
correlated with decreasing motor nerve conduction velocity.  Clinical 
neuropathy appeared only in the patients whose renal function deteriorated the 
most.  This study established clearly the relationship between diminishing renal 
function and the beginning   of uremic neuropathy.  
 
 From the pathological stand point of you, early studies using standard 
histopathology methods suggested that the main pathogenesis of nerve lesion  
was axonal degeneration in a distal distribution (Asbury et al. 17, 21, 22 1963; 
For no and Alston 1967)19 this concept has been substantiated by more recent 
quantitative studies by both Dyck and Thomas and their associates,  who also 
pointed out that some demyelination occurs, apparently as a secondary event in 
fibers in the early stages of Axonal degeneration.  Other authours20 have been 
more impressed by the demyelinative aspects of neuropathy (Dayan et al., 1970 
Dinn and Crane, 1970; Appenzeller et al., 1971) more detailed discussion of the 
morphologic aspects of uremic neuropathy is undertaken in the section entitled 
pathologic features.  
 
 The studies alluded to in the foregoing paragraphs raise, but do not 
answer, the crucial questions about uremic polyneuropathy.  What is the precise 
metabolic defect responsible for the neuropathy?  Where and how does it act?  
Is the specific mechanism in uremic neuropathy also common to other, 
metabolic neuropathies such as deficiency neuropathies or neuropathies due to 
toxins?  How might dialysis methods be modified to prevent or cure the 
neuropathy?  These questions will direct investigation of this condition in the 
coming few years.  
 
DEFINITION  
 
 Chronic kidney disease is defined as renal injury of a more prolonged 
nature, often leads to progressive and irreversible destruction of nephron mass, 
irrespective of cause, the eventual impact of severe reduction in nephron mass is 
an alteration in function of virtually every organ system in the body.1 
Causes of Chronic Kidney disease  
 
Vascular 
 
Renal artery stenosis (only when bilateral or affecting solitary functioning 
kidney) 
Hypertensive nephrosclerosis  
Systemic sclerosis   
Haemolytic uraemic syndrome/thrombotic thrombocytopenic purpura  
Vasculitis (polyarteritis, wegener’s) 
 
Glomerulopathy 
 
All causes of primary glomerulopathy (Except minimal change) 
All causes of secondary glomerulopathy (with associated multi system disease, 
e.g., SLE, Henoch-Schonlein purpura) 
Toxic glomerulopathy (gold, pencillamine) 
 
Tubulointerstitial nephropathy (TN)  
 
Idiopathic 
Associated with multisystem disease (Sjogren’s, sarcoidosis) 
Associated with metabolic disorders (e.g. urate, nephrocalciniosis) 
Toxic e.g. analgesic abuse, Bence-Jones’ protein in myeloma 
 
Infection  
Chronic pyelonephritis 
Renal tuberculosis 
Cystic disease 
Adult polycystic disease 
 
Obstructive nephropathy 
Diabetic nephropathy 
Amyloidosis 
Renal dysphasia, hyperplasia, agenesis 
 
KDOQI staging of chronic kidney disease  
 
Stage  Description  GFR ml /mt per 1.73 m2 
1. Kidney damage with normal GFR  
or increased GFR 
 90  
2. Kidney damage with mildly decreased GFR 60-89 
3. Kidney damage with moderately decreased 
GFR 
32-59 
4. Kidney damage with  severely decreased 
GFR 
15-29  
5. Renal failure  < 15 
 
   
 
 Technically, measurement of total glomerual filtration rate is not 
possible, alternatively creatinine clearance test must be followed to assess the 
approximate values of total glomerular filtration rate even though if there is a 
slight difference from the above.  
 
 
 
1. Cockcroft – Gault  Equation  
       (140 –age) x Body weight in Kg  
 
2.  Equation from the modification of diet in renal disease study  
     Estimated GFR  = 1.86 x (Pcr)-1.154  x (age)-0.203 
 
 
 
CLINICAL FEATURES OF UREMIC NEUROPATHY 
 
 Neuropathy occurs in atleast 65% of patients who are about to begin 
dialysis for chronic kidney disease and is perhaps the most common 
neurological consequence of chronic uremia.  It is a distal, symmetrical, mixed 
sensory motor polyneuropathy affecting the lower limbs27 to a greater extent 
than the upper limbs.  It is clinically indistinguishable therefore from the 
neuropathies associated with chronic alcohol abuse, diabetes mellitus, and lupus 
erythematosus to name but a few.  
 
 The rate of progression, severity, prominence of motor or sensory signs, 
and prevalence of dysesthesia are quite variable.  Males are developing 
neuropathy with an incidence several fold greater than females; this difference 
is unexplained.  Individual serological, biochemical abnormalities (Calcium, 
Magnesium, Phosphate, Urea, creatinine) are not correlated well with this or 
any other neurological manifestation of the uremic state. The chronicity and 
severity of kidney disease appear to be the important cause to the development 
of neuropathy.  
72 x Pcr (mg/dl) 
  The restless leg syndrome28 occurs commonly in uremic patients and 
probably heralds peripheral nerve involvement by the Uremic process.  The 
syndrome consists of creeping, crawling, prickling, pruritic sensations deep 
within the lower limbs, which are almost always worst in the evening and are 
relieved by movement of the limbs29.   
 
 These unpleasant sensations are usually localized to the legs but 
occasionally occur in the thighs and feet as well as in the upper limbs.  
 
 The pathogenesis of the restless legs syndrome is not clear.  Peripheral 
nerve dysfunction probably gives rise to the syndrome.  It has been described in 
association with diabetic neuropathy, avitaminosis & carcinoma.  
Circumstances in which peripheral neuropathy function is often impaired, 
however restless legs has also occurred in barbiturate withdrawal.  Exposure to 
cold, prochlorperazine therapy and pregnancy and the symptoms are aggravated 
by concurrent depressive reactions the precise origin of the disorder remain 
unclear. 
 
 Burning feet identical to that phenomenon encountered in alcoholics and 
in arsenical neuropathy has been described as an early manifestation of uremic 
neuropathy.  Unpleasant tingling, band like constrictions, swelling sensations 
and tenderness in the distal extremities are some of the paresthesias described 
by the majority of patients with early uremic neuropathy.  
 
 Muscle cramps of the distal limbs occur commonly in uremic patients and 
many of these patients lack evidence of neuropathy or tetany.  30Since cramps 
occur commonly in uremia.  They probably represent either shifts of fluids into 
muscle or the effects of uremic toxins upon muscle or the neuromuscular 
junction.  Impaired vibratory sense in the lower limbs, loss of deep tendon 
reflex and ankle jerks followed by knee jerk is the usual first signs of uremic 
neuropathy.  The rate of progression of neuropathy varies widely among 
patients; in general it evolves over several months and the upper extremities 
may become involved.  On occasion a fulminant course occurs and some 
patients develop a disabling flaccid quadriplegia.  In some patient’s distal 
weakness, muscle atrophy and sensory loss progress over several months then 
plateau and remain stationary despite worsening of kidney disease.  The factors 
that determine these differences in the clinical course of neuropathy are unclear.  
 
PATHOGENESIS OF UREMIC NEUROPATHY  
 
 The observation that uremic neuropathy improves with haemodialysis has 
led most observers to conclude that neuropathy result from the accumulation of 
a dialyzable metabolite.  Scrbner31 has speculated that these substances might be 
in the middle molecule range, compounds of this size may cross most dialysis 
membranes more slowly than smaller molecules such as creatinine and urea 
which are the usual measures of chemical control of uremia.  Thus one might 
theoretically achieve chemical control of uremia, while failing to remove the 
putative toxins.  
 
 Supporting this contention have been the observations that (1) control of 
neuropathy may in some cases be dependent upon increased hours of dialysis 
per week, beyond that which is necessary for chemical control of uremia and (2) 
some patients maintained on peritoneal dialysis appear to have a lower 
incidence of neuropathy.  
 
 Such observations suggest that the peritoneal membrane may permit 
passage of some toxic molecules more readily and selectively that the 
cellophane membranes used in hemodialysis. In one study, however, in which 5 
uremic patients with neuropathy and 25 without neuropathy were studied, the 
correlation between a calculated middle molecule concentration and the 
presence of neuropathy was poor.  The “middle molecule” hypothesis is thus 
attractive but there is as yet little rigorous evidence to support it.  
 
 How a dialyzable toxin might produce neuropathy is of some interest.  A 
suggestion that transketolase33, 34 a thiamine – dependant enzyme in the pentose 
phosphate shunt, found in erythrocytes, neural tissue, and elsewhere, is inhibited 
by uremic toxins” was intriguing because of the clinical and pathological 
similarities between uremic and thiamine-deficiency neuropathy.  However, 
several groups have failed to find any alterations of erythrocyte transketolase34 
activity in uremic patients before or after hemodialysis. 
 
 Because of the varying nutritional status of uremic patients, the 
possibility that vitamin deficiency is a mechanism of neuropathy should be 
considered.  Massive doses of vitamins administered both orally and 
parenterally have failed to influence clearly the course of neuropathy in 
informal trails.  This experience has led to general agreement that uremic 
neuropathy is not a result of vitamin deficiency.  Elevations of plasma 
myoinositol levels in uremic patients have led to speculation that this compound 
bears on the problem of neuropathy.  Myoinositol 37 is a water-soluble, cyclic 
hexitol, with a molecular weight of 180.  It is a precursor of the 
phosphoinositides.  A class of phospholipids whose rapid turnover in neural 
tissue has resulted in speculation linking their metabolism to the functional 
activity of nerve.  The kidney probably plays an important role in both 
myoinositol metabolism and excretions.  Hypermyoinositolemia has been 
produced in rats with a diet that contains 35 percent myoinositol;38 slowed 
motor nerve conduction velocities were induced in the sciatic nerves of these 
animals.  Conduction velocities became normal after a normal diet was 
instituted.   However, the possibility that elevated plasma myoinositol levels 
may play a role in the pathogenesis of urmeic neuropathy must be evaluated 
further.  
 
 An inhibitory effect of uremic toxins upon endoplasmic flow of 
transmitters or other essential neural nutrients, as has been shown by pleasure et 
al, for acryl amide-induced neuropathy.  Is an interesting possibility which has 
not yet been tested?  
PATHOPHYSIOLOGY OF UREMIC NEUROPATHY 
 
 Some confusion regarding the essential morbid anatomy of uremic 
neuropathy appears to have been created by several studies.  In which the 
demyelinative aspects of the neuropathy were emphasized and the disorder was 
widely presumed to be caused by a metabolic dysfunction of Schwann cells.  
However, the original clinical and pathological description of the disorder by 
Asbury, victor, 20, 21, 22 and Adams has now been amply corroborated and 
appears to be a primary axonal degeneration with secondary segmental 
demyelination; the segmental loss of myelin is consequent to an abnormality in 
the axon cylinder, which most likely reflects a metabolic failure39 of the 
perikaryon.  The pathological findings are not specific for uremia; they are more 
easily distinguishable from the findings in alcoholic neuropathy, for example, 
another axonal degeneration which is also more severe in the distal aspects of 
the neuron.  All fiber sized, both myelinated and unmyelinated, are affected, 
although the largest and most distal fibers are selectively vulnerable,  Segmental 
demyelination occurs in those fibers about to undergo breakdown, although 
nerve fibers degeneration rapidly probably by pass the demyelinative phase.  
Qualitative changes seen on   electron microscopy include splitting of the 
myelin lamellae and separation from the abnormalities, and the occurrence of 
membrane-bound collections of glycogen particles in the axonal space as well 
as occasional densely lamellate sausage shaped structures.  No consistent 
abnormalities of microfilaments or neurotubules were recognized.  These 
changes are abnormal but not distinctive for uremic neuropathy.   
 
POTENTIAL “UREMIC NEUROTOXINS” 
 
Metabolic products:- 
 
Urea, amino acids, amines, organic acids, indoles, phenols, creatinine, uric acid, 
myoinositol, sorbitol, sulfates, polyamines, middle molecules.  
 
Guanidine compounds:- 
 
Methylgunidine, guanidine, guanidinosuccinic acid, guanidinoacctic acid, 
guanidinoproprionic acid, glycocyamine, guanidinobutyric acid.  
 
Peptides, hormones, and enzymes:- 
 
Parathyroid hormone, calcitonin, glucagons, natriuretic  peptide growth 
hormone, renin, gastric, transketolase deficiency, thiamine definiciency.  
 
Trace elements:- 
 
Aluminum, tin, lead, cadmium, zinc, mercury, manganese, arsenic, copper, iron.  
 
ROLE OF UREMIC TOXINS 
 
 The etiology of uremic neuropathy remains unclear.  Most theories have 
centered on the role of any of a multitude to “uremic toxins” a partial list of 
uremic toxins currently being investigated. 
 
 Any or all of the agents in table may play a role in the development of 
uremic syndrome.  Despite the vehemence with which various groups of 
investigators defend the prosperities of these substances, the evidence that any 
of these agents are themselves bonafide toxins is poor.  For example  the entire 
theory of the toxic effects of “middle molecules” appears to be based on short-
term observations in a few patients.  Basic investigation of the possible toxicity 
of middle molecules is sparse although much basic work has been done on their 
identification and quantification.  In a recent review, evidence that middle 
molecules were neurotoxin in patients or laboratory animals was found to be 
generally lacking. 
 
UREMIC TOXINS AND NERVE CONDUCTION  
 
 Several “uremic toxins” have been identified whose elevated 
concentrations in plasma appear to correlate with depression of motor nerve 
conduction velocity (MNCV) in patients or laboratory animals42.  however, 
these studies do not take into account that (a) depressed MNCV is cyclical, with 
abnormally low values one day and normal values the next, (b) there is day-to-
day variation in MNCV which approaches 20 percent and (c) the findings of 
depressed MNCV in laboratory animals associated with high plasma levels of 
potential “Uremic neurotoxins” has generally not been conformed in human 
subjects with renal failure43. 
 
 Other uremic toxins have been singled out because their levels in blood 
correlate with depression of MNCV in patients with kidney disease.  Such 
analysis’s have been applied to plasma levels of urea, creatinine, parathyroid 
hormone (PTH), myionositol, transketolase, guanidine derivatives, and middle 
molecules, and even in the presence of intact kidneys72 ,73,74 however, 
Nielsen47 suggested that for a substance to be a  uremic neurotoxin, its blood 
levels should correlate better with a particular manifestation of peripheral nerve 
dysfunction(such as reduced conduction  velocity)  than with a simple reduction 
in GFR, although it is possible to correlate impairment in MNCV with levels in 
blood of various substances,  the best correlation was obtained between reduced 
MNCV and a reduction in GFR, with a coefficient of correlation (r value)  of 
0.68 to 0.84.  it was stated that for a substance to be a uremic neurotoxin it 
should have a better correlation with MNCV than does a reduction in GFR.  As 
can be seen in the Table, nothing correlates better with reduced MNCV than 
GFR.  
 
PARATHYROID HORMONE (PTH) 
 
 Among the potential uremic neurotoxins, the substance which has 
probably received the most recent attention has been PTH.  It has been 
suggested that may be a uremic neurotoxin based on a correlation between 
plasama PTH levels and MNCV in patients with chronic kidney disease, as well 
as possible effect of PTH levels and MNCV in patients with chronic kidney 
disease, as well as a possible effect of PTH on MNCV in dogs42 one way to 
determine the effects of PTH on nerve function is to evaluate nerve function in 
patients who have primary or secondary hyperparathyroidism without kidney 
disease.  Several such studies have been carried out.  Pattern and co-workers 
found that in 16 patients with primary hyperparathyroidism.  MNCV was 
normal and following parathyrodiectomy there was no change.  Furthermore, in 
six patients who have secondary hyperparathyroidism, the MNCV was also 
normal and was not altered by medical treatment of the secondary 
hyperparathyroidism.  49Thus, in patients who have hyperparathyroidism with 
uremia, there is no observable effect of PTH on peripheral nerve function.  
 
 If PTH actually is a Uremic Nerurotoxin and has a rapid effect on nerve 
function, this should be evident in patients or animals with acute kidney disease.  
In 12 patients with acute kidney disease, levels of PTH were more than three 
times the normal value.  Moreover, it was found that in these same patients, the 
MNCV was normal, despite the elevated PTH levels.  The normal MNCV was 
not affected by dialysis for 2 to 6 weeks, nor by the diuretic phase of acute 
kidney disease.  In fact, when the same patients were tested 3 months, after 
recovery of renal function, when PTH levels were normal, MNCV was 
unchanged.  Thus, hyperparathyroidism does not noticeably affect nerve 
function in human with acute kidney disease.  
 
 Several studies have examined the relationship between plasma PTH 
levels and MNCV in patients with chronic kidney disease.  Although Avram 
and co-workers found a relationship between plasma PTH levels and MNCV in 
uremic subjects, this was not confirmed by another group workers.  The data of 
this latter group are summarized.  In 35 Uremic patients treated latter group are 
summarized in 35 Uremic patients treated with chronic haemodialysis, the 
MNCV was no change in MNCV.  A similar pattern was suggested by the 
studies of Teschan and co-workers.  They followed 72 patients for up to 12 
months.  In their patients population, at the time dialysis was begun, GFR 
exceeded 10ml/Min. 
 
 These patients has normal predialysis MNCVs and these were unaffected 
by dialysis.  Thus, in patients with either acute or chronic kidney disease, nerve 
conduction velocities were normal despite high plasma levels of PTH.  There 
was no change of MNCV as a result of either recovery of renal function or 
chronic haemodialysis; there was also no effect of parathyroidectomy.  In 
addition, it is general experience that when patients begin dialysis therapy, 
MNCV either stabilizes or improves.  However, virtually all of these patients 
have elevated plasma PTH levels.  This further suggests lack of any effect of 
PTH on nerve function.  Several studies of the effects of PTH on MNCV in 
dogs have also been carried out.  Although one study showed a fall of MNCV in 
dogs ARG, others suggested that MNCV is normal in dogs with kidney disease 
for 3,5 days and is in fact unaltered after kidney disease of 6 months duration.  
 
 
NERVE CALCIUM AND MYELIN  
 
 It has also been suggested that nerve Ca+2 might rise in animals with 
kidney disease as a consequence of excess amounts of PTH in blood42.   
however, in preliminary studies it was found that nerve Ca+2 declines in 
animals with kidney disease and is abnormally low in dogs with kidney disease 
for periods of 3,5 days to 6 months.  It is appropriate that this should happen.  
Several studies have revealed that most of the Ca+2 in peripheral nerves is 
present in the myelin.  
 
 Additionally, studies from several laboratories have shown that the 
histology in uremic nerve includes, as one of it s most prominent 
manifestations, loss of myelin.  If there is a loss of myelin51.  Then nerve ca+2 
which are probably extensively bound to protein and phospholipids, should fall.  
The concentration of Ca+2 in axonal fluid is probably transported by means of 
calcium –binding protein in nerve.  In fact, a decrement of Ca+2 in nerve 
decreases intraxonal transport by 60 to 80 percent in vitro, contrariwise, 
increased nerve Ca+2 actually increases transport in nerve axons in vitro.  Thus, 
it is reasonable to assume that a decrement in MNCV might occur as a 
consequence of a fall in Ca+2 content in nerve.  This is what appears to happen.  
An increase of nerve Ca+2 might be expected to result in an increase of MNCV.  
Thus, at the present time, none of the so called uremic toxins can be shown to 
affect peripheral nerve function.  Rather, the majority of evidence suggests that 
Uremic neuropathy is related to anatomical nerve damage, which taken months 
to years to develop objective evidence of nerve dysfunction is generally not 
present when GFR exceeds 10ml/min.  The evidence that parathyroid hormone 
plays an important role in the nerve dysfunction is unconvincing.  But recent 
studies support the middle molecular theory for the basis of occurrence of 
Neuropathy.  
Nerve conduction study  
 
 
 Nerve conduction studies allow localization of compressive focal 
neuropathy and detection of polyneuropathy, with distinction between 
demyelination; axonal degeneration and conduction block neuropathies.  
Electromyography detects denervation of muscle, helps to distinguish between 
myopathic and neuropathic weakness, and is diagnostic of myotonias and 
neuromyotonias. Single-fiber electromyography and neuromuscular 
transmission studies are particularly important for diagnosing myasthenia gravis 
and the Lambert Eaton myasthenic syndrome.  
Motor conduction studies 
  
 Maximal motor conduction velocity is measured by applying a 
supramaximal stimulus to a motor nerve at two or more different points along 
its course through bipolar electrodes applied to the skin over the trunk of the 
nerve.  The evoked compound muscle action potential from a muscle supplied 
by this nerve is recorded.  Measurement of the latency from the stimulus to the 
initial rise of the compound muscle action potential, and of the distance between 
the pairs of stimulating electrodes, allows calculation of the conduction velocity 
in m/s along various segments of the nerve.  In the case of the median nerve the 
interval between the stimulus applied at the wrist and the initial rise of the 
muscle action potential in the abductor pollicis brevis is known as the distal 
motor latency.  Motor conduction velocities generally exceed 48m/s in the arms 
and 40 m/s in the leg nerves.  Distal motor latencies (DMLs) vary depending 
upon the particular nerve, the site of stimulation, and the technique employed, 
for the median nerve following stimulation at the wrist, the normal DML is less 
than 4.2 m/s vary depending upon the particular nerve, the site of stimulation, 
and the technique employed for the median nerve following stimulation at the 
wrist, the normal DML is less than 4.2m/s but will be prolonged in carpal tunnel 
syndrome or demyelination neuropathy.  F-wave latencies, which reflect the 
time taken for the antidromic volley to depolarize the motor neuron cell bodies 
within the spinal cord, and then for the passage of the resultant action potential 
to travel orthodromically to the muscle, reflect conduction over proximal 
segments of the nerve and root and the normal values are dependent upon 
height.   
 
Well established methods are now available for studying motor conduction in 
the median, ulnar, and radial nerves in the arm, and in the common peroneal and 
posterior tibial nerves in the leg, and the normal ranges for motor conduction 
parameters have been extensively documented (Liveson and Ms 1992 Binnle et 
al.  1995):  Temperature has a profound effect upon nerve conduction, so the 
skin temperature of the limb should be maintained at 
 25-30 oC, if necessary by prior immersion in warm water or by a radiant heat 
lamp.   
 Blockade of impulse conduction is recognized increasingly as an 
important cause of weakness due to peripheral nerve disease.  This conduction 
block usually reflects failure of action potential propagation through axons at 
sties of severe compression or through segments that are demyelinated.  It is 
especially seen in acutely demyelinated nerves within the first few weeks before 
sodium channel redistribution to the denuded internodal segments of the axon 
allows resumption of conduction, albeit at slowed velocity.  Recently it has been 
recognized that there are neuropathies in which conduction block appears to be 
the primary pathophysilogical process.  In such neuropathies, the block often 
occurs without sufficient associated conduction slowing to point to underlying 
demyelination; multifocal neuropathy with conduction block (section 12,11,13) 
is an important example.  Most frequently, conduction block is partial rather 
than total and it may be diffusely distributed along a length of nerve, rather than  
being tightly localized to a particular site. 
  
This has led to difficulty and dispute about the quantificative definition of 
conduction block.  Patial conduction block leads to three electrophysiological 
abnormalities; 
1. Reduced amplitude and area of the compound muscle action potential 
evoked by nerve stimulation at proximal sites compared to distal different 
authors quote degrees of reduction ranging from 20 to 60 percent (Lewis 
and summer 1982 Cornblath et al. 1991). 
 
2. Dispersion of the compound muscle action potential wave form; however, 
this abnormal temporal dispersion can lead to phase cancellation, 
resulting in the misleading appearance of amplitude reduction of the 
compound muscle action potential.  
 
3. Absent or sparse F-wave responses if the conduction block affects 
proximal nerve segments or the nerve roots.  
 
Sensory nerve action potentials  
 
  Sensory conduction in the median, ulnar, and radial nerves can be 
measured by applying stimuli through ring electrodes upon a finger and then 
recording the sensory nerve action potential through cutaneous electrodes 
applied over the trunk of the nerve (orthodromic conduction).  For other 
nerves, such as the sural, the nerve trunk is stimulated and sensory nerve 
action potentials recorded from surface electrodes (antidromic or 
orthodromic conduction).  The sensory nerve action potential (SNAP) is so 
small that averaging techniques are required following multiple stimuli, and 
occasionally needle recording electrodes inserted close to the nerve are 
required (Kimura 1983; Liveson and Ma 1992; Binnie et al. 1995).   
 
 
 
 
 
 
  
  Sensory nerve action potential amplitudes generally range from 5 
to 50 µV, depending upon the particular nerve being studied, and drop in 
amplitude, or absence of the potential, occurs in axonal degenerative, 
demyelinating, or compressive neuropathies.  Thus a diminished SNAP 
cannot in itself distinguish between these types of neuropathy.  Sensory 
nerve action potentials reflect the integrity of the distal axonal branch of the 
dorsal root ganglion sensory neurons.  They remain normal in disease such 
as spondylitic radiculopathy affecting the spinal nerve roots containing the 
proximal axonal branch of the dorsal root ganglion cell bodies lie outside the 
interverbral foramina (Aminoff et al. 1985). The only exception to this can 
occur in the lower lumbar and sacral nerve roots, in which the dorsal root 
ganglia can lie within the intervertabral foramina and loss of sensory nerve 
action potentials, may occur with spinal disease as well as with peripheral 
nerve disease. Radiculopathy may be confirmed by the finding of 
denervation within limb and paraspinal muscles innervated by the same 
segment.  Sensory nerve conduction latencies and velocities can be measured 
but generally find little usefulness in diagnostic clinical practice.  Routine 
techniques for measuring possible conduction block in sensory nerves have 
not been established.   
 
Uses of nerve conduction studies  
 
Nerve conduction studies are principally used to diagnose focal 
monoeuropathies, usually due to nerve compression, and to detect 
polyneuropathy and determine whether it is due to demyelination or axonal 
degeneration.  The additional uses of detecting conduction block 
neuropathies and in discriminating nerve root disease from polyneuropathy 
are dealt with above.  
 
Focal compressive neuropathy 
 
  Focal compressive neuropathy can be diagnosed 
electrophysiologically for most limb nerves and some truncal nerves.  This is 
particularly useful for median nerve compression in the carpal tunnel and the 
ulnar nerve at the elbow.  Conduction distal to a neuropraxial lesion of a 
peripheral nerve may remain normal at a time when its function is severely 
impaired.  When a nerve is compressed, as in entrapment neuropathies, 
motor and sensory conduction across the site of the lesion may be either lost 
or greatly reduced in speed.  This leads to reduction or loss of the sensory 
action potential in that nerve, and prolongation of the distal motor latency.  
Localized slowing of motor conduction can be demonstrated at some 
entrapment sites, such as compression of the ulnar nerve at the elbow, and 
techniques are now available for measuring conduction over short segments 
of nerve in presumed entrapment neuropathies (liveson and Ma 1992).  
Electromyographic sampling of muscles supplied by a trapped nerve will 
show to what extent axonal degeneration has caused denervation.  This 
generally implies a poorer prospect for recovery of nerve function following 
surgical release of the compression.  
 
  Changes in the electromyogram (EMG), tactile sensibility, and 
nerve conduction after suture or compression of peripheral nerves in human 
subjects have been studied longitudinally (Buchthal and Kuhl 1979).  
Enlargement of re-innervated motor units and marked dispersion of motor 
unit action potentials persisted long after suture.  The sensory nerve action 
potential recovered five times as quickly, and tactile sensibility 10 times, 
after correction of a compressive lesion as after releasing a suture.  After 
relief of compressive lesions, the maximum motor and sensory conduction 
velocity recovered to 80-90 percent of normal within 1 year, but after nerve 
suture it had only reached 65-75 percent of normal after 40 months.  
 
Demyelinating polyneuropathies 
 
 Demyelinating polyneuropathies markedly slow conduction along 
affected nerve trunks.  Sometimes difficulty can arise because reduced 
velocities are seen in profound axonal loss when there is no surviving fast – 
conducting fibers remaining to a grossly denervated muscle.  If demyelination 
chiefly affects the proximal segments of motor fibres, it will be associated with 
normal conduction velocity measurements along distal segments.  In this case, 
prolonged F-wave responses are a clue to proximal conduction slowing.  
Criteria have been proposed for defining a neuropathy as demyelinating in 
nature (ad Hoc subcommittee of American academy of Neurology AIDS Task 
Force 1991) in outline these require three out of four of the following 
abnormalities, affecting tow or more nerves: 
1. Reduction of motor velocity to less than 80 percent of the lower limit of 
normal (which represent <39 m/s for arm nerves and <34 m/s for leg 
nerves); 
 
2. Partial conduction block of greater than 20 percent or abnormal temporal 
dispersion causing greater than 15 percent change in duration not 
attributable to an entrapment neuropathy; 
 
3. prolonged distal motor latencies exceeding more than 125 percent of the 
upper limit of normal; 
 
4. Prolonged F-wave latencies greater than 125 percent of the upper limit of 
normal.  
 
 Such stringent criteria, while useful in established disease, are not met 
early in the course of mild forms of chronic idiopathic demyelinating 
polyneuropathy.  Furthermore, sometimes these criteria can only be satisfied 
by exhaustive electrophysiological study of numerous individual peripheral 
nerves.  Most demyelinating neuropathies also involve sensory fibers, with 
reduced amplitude or absent sensory nerve action potentials.   
 
Axonal degeneration polyneuropathies 
 
 Axonal degeneration polyneuropathies usually involve a dying back 
process which mainly affects the longest axons.  The earliest evidence of axonal 
polyneuropathy is electromyographic evidence of denervation of foot and hand 
muscles, coupled with reduced amplitude or absence of sensory nerve action 
potentials in the feet and hands.  The muscle denervation is evident on surface 
electromyography by reduction in the amplitude of compound muscle action 
potentials, which normally range from 10 to 25 m V in hand muscles.  
Concentric needle electrodes inserted into denervated muscle will reveal 
fibrillation potentials and positive sharp waves. Early on the motor conduction 
velocity in surviving axons will be normal, or only marginally reduced.  
However, as severe denervation sets in and the large-diameter axons are lost, 
the motor conduction velocity can fall markedly but rarely to less than 80 
percent of the lower limit of normal and the distal motor latency can rise, but 
rarely above 125 percentage of the upper limit of normal (Corbnlath et al 1992). 
 
 This means that primarily demyelinating polyneuropathies can be 
distinguished electrophysiologically from axonal degeneration.  However, in 
practice, a number of polyneuropathies involve mixed elements of 
demyelination and axonal degeneration and sometimes evade confident clinical 
or electrophysiological classification into either category.  
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MATERIALS AND METHODS 
 
 The study was conducted at the medical wards of Tirunelveli medical 
college hospital, Tirunelveli during the period of May 2004 – May 2006 
Patients with proved clinical, bio-chemical parameters in favour of chronic 
kidney disease are included in this study.  All patients included in this study 
were not on dialysis. 
 
 Inclusion criteria for chronic kidney disease 
             1.  Serum creatinine more than 2 mg %   
                                         2. Creatinine clearance < 40 ml /mt 
                                             Calculated using the formula   
                                              Cockcroft – Gault Equation 
  
                                       
               3. Ultrasound abdomen – kidney size < 9 cm 
          Exclusion criteria:   Patients with other recognizable risk factors for 
peripheral neuropathy are excluded from the study. 
    Diabetes mellitus  
                                         Alcoholism  
                                         Drug induced peripheral neuropathy  
                                         Hansen’s disease 
(140 – age) x Body weight in kg 
72 x Pcr (mg/dl) 
 
=  
 Totally 74 patients were studied.  The duration of renal failure varies 
from 3 months to 7 years.  
A detailed history was taken in all patients with special reference to  
1. Renal symptoms like scanty micturition 
                 Swelling of legs, face 
         Loss of appetite 
        Nausea, vomiting and 
         Pruritis. 
2. Symptoms in favour of peripheral nerve involvement like  
                                      numbness 
          pins and needle sensation 
                                      defective appreciation of pain and  
                                      weakness, thinning of muscles were also asked for.  
3. Symptoms suggestive of autonomic disturbances like  
absence of sweating,  
variation of skin temperature, 
 postural giddiness,  
post micturition dribbling,  
fecal incontinence,  
defective sexual dysfunction in the form of failure of erection or ejaculation 
were elicited.  
4. An elaborated clinical examination was done in all patients with special 
reference to anemia, skin changes, peripheral nerve thickening, sensory and 
motor signs (especially ankle reflex) were looked for.    
5.  Bio-chemical parameters pertaining to renal dysfunction like  
 Blood urea 
 Serum creatinine 
 Creatinine clearance 
 Serum electrolytes were done for all patients.  
Blood hemogram, urine analysis, X-ray chest,  and ECG were taken for all these 
patients.   
Supportive evidences like diagnostic ultrasound is taken as a diagnostic tool to 
assess the size of the kidney as kidneys are contracted in chronic kidney disease. 
Normal kidney size ranges from 9 to 12 cm.  In chronic medical renal disease, 
the size of the kidney is usually less than 9 cm. 
After selecting  the patients with reference to inclusion and exclusion criterias, 
the presence of peripheral nerve dysfunction is assessed in them 
1. CLINICALLY by means of motor and sensory symptoms and signs. 
2. ELECTROPHYSIOLOGICAL STUDIES – Nerve conduction studies   
      Clinical features like peripheral sensory loss, pin and needle sensation, 
burning feet sensation, distal muscle weakness and distal reflex loss are 
taken as indicators of clinical peripheral nerve dysfunction.  
     
Nerve conduction studies are done in all patients. 
  A suitable nerve is selected so that it can be stimulated at two points 
along its course and the response is recorded by using the surface electrodes 
placed over the muscle, supplied by that particular nerve.  
 
 The following nerve conduction studies were performed in all patients on 
all 4 limbs.  
 Motor nerve conduction study of Median nerve 
        Ulnar nerve 
        Peroneal nerve 
                 Tibial nerve    
Sensory conduction study of Median nerve 
                         Ulnar nerve 
                                                    Sural nerves were done in all patients. 
 
 In the motor nerve conduction study, the distal latency, amplitude of 
compound muscle action potential conduction velocity and latency of F waves 
were studied. In the sensory conduction study the latency and amplitude of 
sensory action potential were studied.  
 
 
 
The following criterias are taken as evidences of peripheral neuropathy. 
MOTOR NERVE CONDUCTION VELOCITY   
- Motor nerve conduction velocity < 40 m/sec 
- Delayed distal latency  
- Fall  in amplitude of compound muscle action potential  > 30% between 
proximal and distal stimulation.   
SENSORY NERVE CONDUCTION VELOCITY  
- Delay in peak latencies. 
- Reduced sensory nerve action potential. 
      Statistical analysis was done with inference using students T test, chi square      
and averages. 
 
 
 
 
 
 
 
 
 
  
OBSERVATION 
 
 
TABLE 1 
 
NO OF PATIENTS AFFECTED VERSUS TOTAL NUMBER OF PATIENTS  
ASSESSED IN PERCENTAGE  
 
 
 
Total No. Of Patients 
  
 
Patients With Peripheral Nerve Dysfunction  
 
74 
 
48 (65%) 
 
 
 
 
Numbers of patients affected with chronic kidney disease were 74. 
Out of 74 patients assessed, 48 patients proved to have peripheral nerve 
dysfunction by electrodiagnostic study.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE II 
 
 
NO OF PATIENTS AFFECTED MALE AND FEMALE VERSUS TOTAL 
  
NUMBER OF PATIENTS AFFECTED 
 
 
 
Total No Patients With Peripheral Nerve  
Dysfunction  
 
 
No. Of 
Male 
 
No Of 
Female 
 
48 
 
 
36 
 
12 
 
 
 
 
The numbers of patients with peripheral nerve dysfunction were 48. 
Among these, 36 patients were male and 12 were female. 
 
 
 
 
TABLE III 
Peripheral nerve dysfunction and age group 
NUMBER OF PATIENTS AFFECTED WITH REFERENCE TO AGE GROUP 
 
 
Age group 
 
 
Total 
 
Affected 
 
15-24 
 
 
10 
6 
 
25 to 34 
 
 
12 
11 
 
35-44 
 
21 13 
 
45 to 54 
 
17 10 
 
55-64 
 
8 3 
 
65-74 
 
6 5 
 
Total 
 
74 48 
Mean 
 
42.6 41.7 
 
S.D 
 
 
14.3 
 
14.6 
 
P > 0.05 
 6 patients affected were in the age group 15 – 24 years, 11 patients in the 
age group 25 – 34 years, 13 patients in the age group 35 – 44 years, 10 patients 
in the age group 45 – 54 years, 3 patients in the age group 55 – 64 years, 5 
patients in the age group 64 – 74 years The above table reveals that the affected 
patients are more in the age group 35 – 44 years.    
  
TABLE IV 
 
NO OF PATIENTS AFFECTED BY PERIPHERAL NERVE DYSFUNCTION 
IN CHRONIC KIDNEY DISEASE VERSUS DURATION OF DISEASE 
 
Duration of chronic kidney 
disease 
 
 
Total no of 
patients 
 
No patients with p.n. 
dysfunction 
 
< 1 years 
 
 
11 
 
4(36%) 
 
1-3 years 
 
 
21 
 
11(52%) 
 
3-5 years 
 
 
22 
 
 
16(73%) 
 
>5 years 
 
 
20 
 
17(85%) 
 
TOTAL 
 
74 
 
 
                     48 
 
 
 
 
 
 
 
 
 
 
 
Chi square = 8.125  p< 0.01 
 From this table, it is learnt that the number of patients affected with 
peripheral nerve dysfunction is increasing when the duration is increasing (more 
than 5 years).  Statistical analysis done using chi square = 8.125 P < 0.01 so it is 
significant. 
 
 
 
 
 
TABLE V 
 
Type of Peripheral Neuropathy 
 
 
NUMBER OF PATIENTS AFFECTED WITH PERCENTAGE WITH 
REFERENCE TO THE TYPE OF PERIPHERAL NEUROPATHY 
 
SENSORY 
MOTOR 
SENSORY  MOTOR Total  
 
 
25(34%) 
 
 
 
12(16%) 
 
 
 
 
 
11(15%) 
 
 
48(65%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 48 patients had evidence of peripheral neuropathy by electro 
diagnostic study. 25 patients revealed sensory motor neuropathy, 12 
patients had sensory neuropathy and 11 patients had motor neuropathy.  
From  the  table it is observed that the commonest type of neuropathy in 
chronic disease patients is distal  sensory motor neuropathy. 
 
 
 
 
 
 
 
 
Table VI 
 
 
NUMBER OF PATIENTS AFFECTED WITH PERCENTAGE WITH 
REFERENCE TO OVERT AND SUBCLINCAL NEUROPATHY 
 
 
 
OVERT NEUROPATHY SUBCLINICAL NEUROPATHY TOTAL 
14 (19%) 34(46%) 48 (65%) 
 
 
  
 Numbers of patients affected with peripheral neuropathy by 
electrodiagnostic study were 48.  Of these 48, only  14 patients  showed clinical 
evidence of peripheral neuropathy.  Of these  14 patients 11 patients had both 
motor and sensory symptoms in the form of loss of ankle jerk and defective  
vibration sense, 2 patients had numbness both lower limbs, 1 patient had  distal 
muscle weakness of lower limbs. 
 
 
 
 
  
 
TABLE VII 
NO OF MALE AND FEMALE PATIENTS AFFECTED WITH 
REFERENCE TO CREATININE CLEARANCE 
 
 
Total no. of patients 
 
Creatinine clearance ml/mt. 
 M  F  
 
Affected male 
 
Female 
 
<15 
 
 
60% 
 
79% 
 
 
72% 
 
66% 
 
15-29 
 
 
31% 
 
11% 
 
20% 
 
25% 
 
30-59 
 
 
9% 
 
10% 
 
8% 
 
8% 
 
Total  
 
 
100 
 
 
100 
 
 
100 
 
100 
 
 
 72% of males and 66% of females were affected when the creatinine 
clearance was < 15ml/mt. 20% of males and 25% of females were affected 
when the creatinine clearance was 15 – 29 ml/mt.  Males were affected more 
when the creatinine clearance <15 ml/mt. Both sex were affected equally when 
the creatinine clearance between 30 -59 ml/mt. 
  
 From this table, it is observed that 72% of males and 66% of females with 
creatinine clearance below 15ml/mt showed evidence of peripheral neuropathy. 
DISCUSSION 
 
 
 Peripheral neuropathy is a recognized complication of renal failure. This 
study enlightens the incidence and clinical presentation of peripheral nerve 
dysfunction in patients with chronic kidney disease.  
 
 Total numbers of patients studied were 74.   Among the 74 patients 48 
patients showed evidence of peripheral nerve dysfunction either clinically or 
electrophysiologically.  36 male patients showed features of peripheral nerve 
dysfunction and 12 female patients had evidence of peripheral nerve 
dysfunction. From the available data there is some predilection for male in the 
incidence of peripheral neuropathy in patients with chronic kidney disease. 
When creatinine clearance was <15 ml/mt.   
 
 The duration of chronic kidney disease varied from 3 month to 7 years.   
85% of patients showed features of peripheral nerve dysfunction either 
clinically or electrophysiologically when the duration of chronic kidney disease 
is more than 5 years.  This shows that there is a linear correlation between the 
incidence of peripheral neuropathy and duration of chronic kidney disease.  
Patients who were presenting with end stage renal failure had creatinine 
clearance less than 15 ml/mt,  the incidence of peripheral nerve dysfunction was 
more in these patients  than  in patients in whom the creatinine clearance less 
was between 15 -30ml/mt. 
  Jairam, N.Kumar, P.P. Varma discussed nerve condition study in relation 
to duration and severity and chronic kidney disease. They found that reduced 
motor nerve conduction velocity and sensory nerve conduction velocity are 
suggestive of neuropathy but delayed F waves and H reflex are also suggestive 
of neuropathy.   
 
 In this study reduced motor nerve conduction velocity and sensory nerve 
conduction velocity are markers of peripheral neuropathy.  This study doesn’t 
account F waves and H reflex since these are essential for root lesions. 
 
 The common type of peripheral neuropathy observed in this study was 
distal symmetrical sensory motor peripheral neuropathy and incidence of this 
type of sensory motor neuropathy was 34%.   The incidence of sensory 
neuropathy was 16% and motor neuropathy was 15%.  The other types of 
neuropathy mononeuropathy, truncal neuropathies and cranial neuropathies are 
not registered in our clinical study.  
 
   
  
 
 Among these 48 patients,   34 patients had evidence of peripheral 
neuropathy in electrodiagnostic study 14 patients had clinical evidence of 
peripheral neuropathy.  11 patients had both motor and sensory symptoms in the 
form of loss of ankle jerk, defective appreciation of vibration sense. This may 
emphasis earliest clinical sign of neuropathy is loss of ankle jerk.  2 patients had 
numbness of both lower limbs. 1 patient had distal muscle weakness of both 
lower limbs. So incidence of overt neuropathy is 19% and subclinical 
neuropathy is 46%.  
 
 By Rakesh H. shah, Meenakshi Khar, NC. Mehta study, the incidence of 
peripheral neuropathy in chronic kidney disease was 68% and the incidence of 
overt neuropathy and subclinical neuropathy was 21% and 47% respectively.  
 
 In this study the incidence of peripheral neuropathy in chronic kidney 
disease was 65% and the incidence of overt and subclinical neuropathy was 
19% and 47% respectively.  
 
 
 
 
 
 
 
CONCLUSION 
 
 
1. Incidence of peripheral neuropathy is 65% in patients suffering from 
chronic kidney disease. 
2. Distal symmetrical predominantly sensory motor neuropathy is the  
commonest type of peripheral neuropathy observed in patients with 
chronic kidney disease. 
3. Loss of ankle reflex and vibratory sensory loss are the  commonest 
clinical signs of peripheral neuropathy in patients with chronic kidney 
disease. 
4. There is predilection for male in the incidence of peripheral neuropathy in 
chronic kidney disease when the creatinine clearance was below 15ml/mt. 
5. Incidence of peripheral neuropathy is having linear correlation with 
severity and duration of renal failure. 
6. Incidence of subclinical neuropathy is about 46% and overt neuropathy is 
19%. 
 
 
 
 
 
 SUMMARY 
 
  Chronic kidney disease is found to cause peripheral neuropathy in 65% of 
patients both (19%) overt and (46%) subclinical neuropathy of which distal 
symmetrical sensory motor neuropathy is common and the incidence of 
peripheral neuropathy is directly proportional to duration and severity of 
chronic kidney disease.    
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 PROFORMA 
 
Peripheral nerve dysfunction study in chronic renal failure  
 
Name  
Age/sex 
Address 
Occ. Income  
D.O.A 
D.O.D  
PROFILE ABOUT RENAL FAILURE  
 
Duration of illness 
Symptoms  
Scanty urination  
Puffiness of face and body 
Nausea  
Vomiting  
Loss of appetite  
Weakness of the limbs  
Pin and needle sensation, cloth sensation  
Defective appreciation of pain and temperature  
Numbness  
Postural  giddiness  
Sexual dysfunction  
Past history  H/o HT,DM,TB 
H/o smoking Alcohol   
General examinations   
 Anemia  
Jaundice  
Pedal odema    
Peripheral nerve thickening  
Pulse, BP  
Examination of CNS higher function, cranial nerves, spino motor system, 
sensory system. 
Investigations  
Urine albumin 
           Sugar  
 Deposit   
Blood TC,DC,Hb 
Blood sugar  
Blood urea 
Serum creatinine  
X-ray chest 
ECG 
Ultra sound abdomen 
ELECTROPHYSIOLOGICAL EVALUATION 
Conduction velocity  
Upper limb  
Ulnar nerve  Motor  
 Sensory  
 
Median nerve  Motor  
  
 
Anterior tibial nerve  Motor  
 Sensory 
 
Common 
 peroneal nerve  
Motor 
 Sensory  
